2026· International review of neurobiology· Vol 187, pp.
91-132
· 0 citations
Medicine
TL;DR
This chapter summarises the mechanistic framework linking bioenergetic breakdown to AD pathology, with potential therapeutic opportunities aimed at restoring mitochondrial function, enhancing glucose utilisation, and correcting insulin signalling, further opening new avenues for multimodal interventions and identification of progressive metabolic dysfunction biomarkers to aid diagnostic processes.
Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder involving metabolic dysfunction, neuroinflammation, mitochondrial impairment, synaptic failure, and neuronal loss. Although amyloid-beta deposition and neurofibrillary tangles composed of hyperphosphorylated tau remain central patho...
Jefferson Muniz Alves da Silva, A. Kümmerle, D. A. Rodrigues et al.· Future Medicinal Chemistry· 0 citations
Alzheimer’s Disease (AD) is a neurodegenerative disorder with
progressive cognitive decline, β-amyloid plaques, neurofibrillary tangles, oxidative stress,
and neuroinflammatory responses. So far, the pathogenesis of AD has been explained by
the cholinergic hypothesis, amyloid cascade hypothesis, and tau protein dys...
Lalit Parihar, A. Singh, Sanjar Alam· Current Pharmacogenomics and...· 0 citations
Alzheimer’s disease (AD) has been conceptualised as a proteinopathy driven by amyloid-β plaques and hyperphosphorylated tau neurofibrillary tangles. AD should not be understood as exclusively a proteinopathy or a metabolic/redox disorder, but as a network of interacting processes in which metabolic dysfunction, mitocho...
Amador Velázquez de Castro-Bono, G. Castro-Luna, J. Guil-Guerrero· International Journal of Mol...· 0 citations
Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide and poses a major global health challenge. This complex disease involves multiple pathogenic factors, including amyloid-beta (Aβ), tau protein aggregation, synaptic dysfunction, mitochondrial impairment, oxida...
Mona Piplani, Shivani Thakur, Pankaj Kumar et al.· Biomedical & Pharmacolog...· 0 citations
This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction, neurovascular dysfunction, synaptic dysfunction,...
Desh Deepak Singh· Current Neuropharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
